EM
EMMA
Emmaus Life Sciences, Inc.
$0.0115
0.00%
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
May 20, 2026
earnings_calendar
EMMA Q1 2026 Earnings Scheduled — 2026-05-20
Apr 21, 2026
SEC
Emmaus Life Sciences reported a 25% year-over-year revenue decline for 2025 to $12.5 million, driven by U.S. generic com
8-K — Impact 7/10
Apr 17, 2026
SEC
Emmaus Life Sciences appointed Henry H. Du to its Board of Directors and as a member of the Audit Committee, effective A
8-K — Impact 3/10
Mar 4, 2026
SEC
Emmaus Life Sciences entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT) to supply Endari (L-glutamine)
8-K — Impact 4/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Latest Reports
BEARISH
8-K
7/10
Emmaus Life Sciences reported a 25% year-over-year revenue decline for 2025 to $12.5 million, driven by U.S. generic com
Apr 21, 2026
NEUTRAL
8-K
3/10
Emmaus Life Sciences appointed Henry H. Du to its Board of Directors and as a member of the Audit Committee, effective A
Apr 17, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
BEARISH
8-K
7/10
Emmaus Life Sciences reported a 25% year-over-year revenue decline for 2025 to $12.5 million, driven
Apr 21, 2026
NEUTRAL
8-K
3/10
Emmaus Life Sciences appointed Henry H. Du to its Board of Directors and as a member of the Audit Co
Apr 17, 2026
NEUTRAL
8-K
4/10
Emmaus Life Sciences entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT) to supply E
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Nov 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Oct 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Sep 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
earnings_calendar
EMMA Q1 2026 Earnings Scheduled — 2026-05-20
Mar 27, 2026
earnings_calendar
EMMA Q4 2025 Earnings After Market Close — 2026-03-27